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Diabetic retinopathy (DR) is a frequent diabetes-associated complication. Pericyte
dropout can cause increased vascular permeability and contribute to vascular occlusion.
Adipose-derived stromal cells (ASC) have been suggested to replace pericytes and
restore microvascular support as potential therapy of DR. In models of DR, ASC not
only generated a cytoprotective and reparative environment by the secretion of trophic
factors but also engrafted and integrated into the retina in a pericyte-like fashion. The
aim of this study was to compare the pro-angiogenic features of human ASC and
human retinal microvascular pericytes (HRMVPC) in vitro. The proliferation and the
expression of ASC and HRMVPC markers were compared. Adhesion to high glucose-
conditioned endothelial extracellular matrix, mimicking the diabetic microenvironment,
was measured. The angiogenesis-promoting features of both cell types and their
conditioned media on human retinal endothelial cells (EC) were assessed. To identify a
molecular basis for the observed differences, gene expression profiling was performed
using whole-genome microarrays, and data were validated using PCR arrays and
flow cytometry. Based on multiplex cytokine results, functional studies on selected
growth factors were performed to assess their role in angiogenic support. Despite
a distinct heterogeneity in ASC and HRMVPC cultures with an overlap of expressed
markers, ASC differed functionally from HRMVPC. Most importantly, the pro-angiogenic
activity was solely featured by ASC, whereas HRMVPC actively suppressed vascular
network formation. HRMVPC, in contrast to ASC, showed impaired adhesion and
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proliferation on the high glucose-conditioned endothelial extracellular matrix. These
data were supported by gene expression profiles with differentially expressed genes.
The vessel-stabilizing factors were more highly expressed in HRMVPC, and the
angiogenesis-promoting factors were more highly expressed in ASC. The vascular
endothelial growth factor receptor-2 inhibition efficiently abolished the ASC angiogenic
supportive capacities, whereas the addition of angiopoietin-1 and angiopoietin-2 did
not alter these effects. Our results clearly show that ASC are pro-angiogenic, whereas
HRMVPC are marked by anti-angiogenic/EC-stabilizing features. These data support
ASC as pericyte replacement in DR but also suggest a careful risk-to-benefit analysis to
take full advantage of the ASC therapeutic features.
Keywords: human adipose-derived stromal cells, human retinal pericytes, diabetic retinopathy, angiogenesis,
vascular–endothelial growth factor, angiopoietin
INTRODUCTION
Diabetic retinopathy (DR) is a common microvascular
complication of diabetes mellitus with a risk of causing blindness
(Stitt et al., 2016; Hammes, 2018). The early stage of the disease,
known as non-proliferative DR, is diagnosed by microvascular
abnormalities. These are the consequence of a sequela of
detrimental events, which involve the whole neurovascular
retina and include pericyte dropout, basal lamina thickening,
and endothelial, neuronal, and glial dysfunction (Stitt et al.,
2016; Fiori et al., 2018; Hammes, 2018). Reactive, uncontrolled
mechanisms cause angiogenesis, leading to proliferative DR.
To date, treatments of sight-threatening DR include laser
photocoagulation, vitreoretinal surgery, corticosteroids, and—
more recently—anti-vascular endothelial growth factor (VEGF)
drugs to limit and reduce the pathological hyperproliferation of
retinal vessels (Stitt et al., 2016; Hammes, 2018). To avoid the
associated side effects, cell-based therapies have been suggested
(Stitt et al., 2011).
Loss of pericytes appears as the earliest event, causing
destabilization of the retinal vessels (Pfister et al., 2013).
Destructive signaling pathways involving the angiopoietin–
Tie2 axis can lead to pericyte detachment and migration
and, sometimes, subsequent apoptosis (Beltramo and Porta,
2013). Therefore, the prevention and/or the containment of
DR progression may involve the control of pericyte dropout to
promote vascular repair and the reversal of ischemic injury.
Therapy with mesenchymal stromal cells (MSC), especially
those sourced from adipose tissue (adipose-derived stromal cells,
ASC), emerged as an interesting treatment option for DR due to
their pro-regenerative, pro-angiogenic, anti-apoptotic, and anti-
inflammatory functions and their close relationship to pericytes
(Fiori et al., 2018). Indeed the first hint came from a study
where intravenously infused MSC improved the blood–retina
barrier integrity (Yang et al., 2010). At this stage, it was not
clear whether the observed effect was directly linked to the local
action of the infused cells or secondary to lowered hyperglycemia.
Subsequent data provided better insight, indicating that ASC not
only generate a cytoprotective and regenerative environment by
secretion of trophic factors acting on endothelial, neuronal, and
glial cells (Ezquer et al., 2016) but also engraft and integrate
into the retina in a pericyte-like fashion (Mendel et al., 2013).
In different models of DR, ASC wrapped around retinal vessels
and expressed α smooth muscle actin (α-SMA) upon intravitreal
injection. This went with an improvement of visual function and
delay in disease progression (Mendel et al., 2013; Rajashekhar
et al., 2014; Hajmousa et al., 2018). In vitro tube formation
assays complemented these observations, indicating that ASC can
support and stabilize capillary structures (Merfeld-Clauss et al.,
2010). However, there are discrepant data on whether ASC can
effectively migrate, integrate, and differentiate gaining pericyte-
like functions or rather exert their function by paracrine effects.
Ezquer et al. (2016) observed that the cells remained in the
vitreous without signs of differentiation and acted via secreted
factors. In contrast, (Cronk et al., 2015) observed that only
cells, but not the conditioned medium, were vasoprotective. Our
previous data indicate that cell–cell interactions via NOTCH-
2 are required for in vitro tube formation, but not for in vivo
angiogenesis, which appeared to be independent of NOTCH-2,
mainly based on paracrine factors (Terlizzi et al., 2018).
Besides the uncertainties in understanding the effective mode
of action of MSC/ASC in DR, another concern regarding
MSC therapy is that the cells should resist the diabetic
microenvironment, which may impair the MSC pro-regenerative
function (Cianfarani et al., 2013; Rennert et al., 2014; Cronk
et al., 2015). However, others and we have shown that ASC resist
hyperglycemic stress and restore the angiogenic properties of
endothelial cells (EC) which were suppressed by hyperglycemia
(Rajashekhar et al., 2014; Hajmousa et al., 2018; Fiori et al., 2020).
Furthermore, the MSC-mediated secretion of pro-angiogenic
factors may represent a significant risk as these factors may
worsen DR by promoting vessel proliferation (Beltramo et al.,
2014). In fact, we observed that the intravitreal injection of MSC
into non-diabetic transgenic animals induced cataract, pericyte
loss, vascular dysfunction, and inflammatory responses, thus
worsening the established retinopathy (Huang et al., 2019).
To clarify whether ASC can take over pericyte functions, we
compared the pro-angiogenic and the pericyte-like functions
of human ASC and human retinal microvascular pericytes
(HRMVPC) in vitro to elucidate the differences and the
similarities between these two cell types. Intriguingly, the
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pro-angiogenic activity was solely featured by ASC, whereas
HRMVPC actively suppressed the vascular network formation.
MATERIALS AND METHODS
Cell Culture
All protocols for isolating the primary cells were approved by the
Mannheim Ethics Commission II, except for the cells provided
by collaboration or commercial sources. All donors gave written
informed consent in accordance with the Declaration of Helsinki.
Human umbilical vein endothelial cells (HUVEC), initially
used as a model of EC, were isolated as described before (Bieback
et al., 2013) and cultivated at 8,000 cells/cm2 in endothelial cell
growth medium-2 (ECGM-2 with 1 g/L glucose; PromoCell,
Heidelberg, Germany). HUVEC, derived from different donors,
were used from passages 3 to 5. Human retinal microvascular
endothelial cells (HRMVEC; two different donor isolates,
passage 3; PeloBiotech, Planegg, Germany), used to reflect the
microvascular retinal milieu, were cultured similar to HUVEC
and used until passage 8. For some experiments, EC were cultured
in normal glucose (NG; 1 g/L standard concentration in all
culture media used), high glucose (HG; 4.5 g/L), or mannitol
as osmotic control, adding additional 3.5 g/L glucose/mannitol
to the media. Adipose-derived stromal cells (ASC) were isolated
from lipoaspirate as described previously (Bieback et al., 2012).
The ASC were cultured at seeding densities of 200 ASC/cm2 in
Dulbecco’s modified Eagles medium (DMEM) with 10% human
AB serum (1 g/L glucose; PAN Biotech, Aidenbach, Germany
and German Red Cross Blood Donor Service, respectively),
1% penicillin/streptomycin (PAN Biotech), and 2% L-glutamine
(200 mM; PAN Biotech). Different donor isolates, passages 2
to 4, were used throughout the study to account for donor-
specific variances. The immortalized human retinal pericytes
(Bmi-HRMVPC; passage 6; kindly provided by Elena Beltramo),
initially used for comparison, were cultured by seeding 20,000
cells/cm2 in DMEM 10% fetal bovine serum (FBS; Sigma-Aldrich
Chemie GmbH, Munich, Germany) and used at passages 7 to
8. In addition, three different isolates of primary human retinal
microvascular pericytes (HRMVPC, passage 3) were purchased
to account for donor-specific differences. The HRMVPC were
cultured by seeding 20,000 cells/cm2 in pericyte growth medium
in flasks coated with Speed Coating Solution (all PeloBiotech) and
used from passages 4 to 6.
All cells were cultured at 37◦C with 5% CO2 and the medium
was changed every 2 to 3 days. All cells were cryopreserved using
90% FBS and 10% dimethyl sulfoxide (Wak-chemie Medical
GmbH, Steinbach, Germany).
GFP and dTomato Expressing HUVEC and HRMVEC
To monitor angiogenesis, EC were transduced to express GFP or
dTomato. The GFP- or dTomato-expressing plasmids pHR’SIN-
cPPT-SEW, together with pCMV-DR8.91 and pMD.G (all kindly
provided by Prof. Patrick Maier, Department of Radiation
Oncology, University Medical Centre Mannheim, Germany),
were used to produce lentiviral vectors through the transient
transfection of 293FT cells. The HUVEC and HRMVEC were
transduced once in the presence of polybrene (8 µg/ml; Sigma-
Aldrich). The transduced GFP- or dTomato-positive EC were
sorted using a BD FACSAria IIu (Becton Dickinson, Heidelberg,
Germany), collected, and cultured as reported previously. The
transduced EC were used from passages 5 to 11.
Comparative Characterization of Human
ASC and HRMVPC
The growth curves of ASC, HRMVPC, and Bmi-HRMVPC
were assessed by seeding 2,500 cells/cm2 in 96-well plates
in eight technical replicates and recording the increasing
confluence every 2 to 4 h using a live imaging device (IncuCyte
ZOOM; Essen BioScience, Ann Arbor, MI, United States)
(Supplementary Figure S1). The percent confluence
was determined using an adapted processing definition
(IncuCyte R© ZOOM software).
Multiparametric flow cytometry was performed on
10,000 trypsinized cells using the titrated antibodies listed
in Supplementary Table S1, using a BD FACSCanto II (Becton
Dickinson) running BD FACSDIVA software. The obtained data
were analyzed with FlowJo software (FlowJo, LLC, Ashland,
OR, United States). The percentage positivity and the mean
fluorescence intensity (MFI) values were calculated against
unstained controls. All antibodies were validated using a positive
control, except for the regulator of G protein signaling 5 (RGS5),
where putative positive controls yielded negative results despite
using different antibody clones and direct, indirect, extracellular,
and intracellular staining. These data, thus, are not shown.
Interaction of ASC and HRMVPC With
High Glucose-Conditioned Endothelial
Extracellular Matrix
To compare the interaction between ASC, Bmi-HRMVPC, and
HRMVPC on HG-conditioned EC extracellular matrix (ECM),
we followed the protocol by Beltramo et al. (2009) with slight
modifications. Briefly, the HUVEC (15,000 cells/cm2) or the
HRMVEC (7,500 or 10,000 cells/cm2) were cultured in 24-well
plates. The HUVEC were seeded in 1/4 ECGM-2 (ECGM-2 with
75% reduced growth supplements) at NG or HG conditions.
We have previously observed that only upon lowering the
growth factor content did the negative HG effects on EC
became apparent (Fiori et al., 2020). Mannitol (3.5 g/L) served
as osmotic control. The HRMVEC were seeded in standard
ECGM-2 at NG or HG conditions. Upon reaching at least 95%
confluence, as monitored by kinetic live cell imaging (IncuCyte
ZOOM), the EC were washed once with phosphate-buffered
saline (PBS) and lysed with 0.25 mM ammonia solution for
3 min. The obtained ECM was washed thrice with PBS and
kept wet until use. The intactness of the ECM was verified
by brilliant blue stain (Supplementary Figure S2). The ASC
or HRMVPC were seeded on top of the ECM at a density
of 5,000 cells/cm2. Using kinetic live imaging, adhesion was
monitored after 10 and 20 min and proliferation was monitored
every 2 h for 2 days. The average single cell area was
assessed during adhesion and cell confluence/proliferation using
individually adapted segmentation masks/processing definitions
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(Supplementary Figure S2). Single measurements were excluded
when confounded by debris or image analysis errors. The average
of the technical replicate values in each individual experiment was
normalized to NG control and used to calculate the mean values
and the standard deviation for the biological replicates.
Angiogenesis Assays
To assess the vascular network/tube formation of EC and
the pro-angiogenic potential of ASC and HRMVPC, two
angiogenesis assays were used—one dedicated to assess the
supportive action of the ASC/HRMVPC seeded as a monolayer
and the other to assess the pro-angiogenic activity of the
conditioned medium (CM).
Coculture (CC) Angiogenesis Assay
A total of 30,000 ASC or HRMVPC were seeded per well in a
96-well plate in 1/4 ECGM-2 for 1 h, and 1/4 ECGM-2 was used
to keep the endothelial growth factor concentrations low. Then,
5,000 (in later passages 8,000) GFP or dTomato HUVEC or GFP
or dTomato HRMVEC were seeded in 1/4 ECGM-2 on top of the
monolayer. The cocultures were incubated for 72 h. Visualization
of tube formation over time was performed by taking phase-
contrast and fluorescent images with the IncuCyte ZOOM
imaging device (Supplementary Figure S3A). An integrated
angiogenesis algorithm measured tube formation by calculating
the tube length, area, and number of branch points. After 72 h of
coculture, CM was collected and frozen at−80◦C. The respective
monoculture-derived CM was prepared in parallel; 1/4 ECGM-2
served as control.
Basal Lamina Matrix (BM) Angiogenesis Assay
A total of 17,000 GFP or dTomato HRMVEC were seeded per
well in a 96-well plate on top of a 50-µl/well layer of a basal
lamina matrix (GeltrexTM LDEV-free reduced growth factor
matrix; Thermo Fisher Scientific, United States) in 1/4 ECGM-2
or CM of the CC angiogenesis assay. Fluorescent images were
taken every 30 min with the IncuCyte ZOOM live imaging
device (Supplementary Figure S3A). Network formation was
monitored for up to 6 h and maximum values of branch points
(1/mm2) and network length (mm/mm2) were calculated using
either NIH ImageJ with the Angiogenesis Analyzer plugin or the
IncuCyte Software. Network branch point metrics were used for
statistical analyses. Because ASC showed network formation in
the BM angiogenesis assay similar to EC, we did not run direct
cocultures in this assay but used it to analyze the CM effects on
HRMVEC tube formation.
Conditioned Medium, Inhibitors, and Growth Factor
Addition
When specified, CM derived from either CC angiogenesis
assays or monocultures, cultured for 72 h in 1/4 ECGM-2,
was added to both angiogenesis assays instead of the control
medium. Furthermore, the following substances were used:
recombinant human vascular endothelial growth factor
(rhVEGF165, 10 ng/ml; PeproTech, London, United Kingdom),
angiopoietin-1 and angiopoietin-2 [rhAng-1 and rhAng-2,
400 ng/ml (Teichert et al., 2017); both PeproTech], suramin
sodium (anti-angiogenic compound, 100 µM; Santa Cruz
Biotechnology, Heidelberg, Germany), and ZM 323881
hydrochloride [selective VEGFR2 antagonist, 1 µM (Busceti
et al., 2017); Santa Cruz Biotechnology].
Immunofluorescence Staining
To assess pericyte-like differentiation upon network formation,
the expression of pericyte markers α-smooth muscle actin
(α-SMA), neural/glial antigen 2 (NG-2), regulator of G protein
signaling 5 (RGS5), and platelet-derived growth factor receptor-
β (PDGFR-β) (Bergers and Song, 2005) was assessed in CC
angiogenesis cocultures. A total of 100,000 ASC/well were seeded
in 1/4 ECGM-2 medium in eight-well µ-slides (ibidi, Gräfelfing,
Germany) and then 20,000 dTomato HRMVEC were seeded on
top. Network formation was monitored over 72 h. Then, the
wells were washed with PBS and fixed with 2% paraformaldehyde
in PBS for 30 min. After washing, the cells were permeabilized
with 0.5% Triton X-100. After 15 min of blocking with
2% bovine serum albumin (BSA), 50 µl/well of ready-to-use
mouse anti-human α-SMA (Progen, Heidelberg, Germany),
mouse anti-human NG-2 (1:100; Santa Cruz Biotechnology),
mouse anti-human RGS5 (RGS5 and RGS5-AF647 clone B4,
1:100; Santa Cruz Biotechnology or clone OTI1C1; OriGene
Technologies, Rockville, MD, United States), or mouse anti-
human PDGFR-β (clone 18A2, 1:100; Santa Cruz Biotechnology)
were added and incubated for 1 h in the dark. After washing
with 0.1% BSA, secondary antibody anti-mouse-Alexa Fluor
488 F(ab’)2 (1:1,000 final dilution, Invitrogen, Thermo Fisher
Scientific, Karlsruhe, Germany) was added for 1 h in the
dark. The nuclei were counterstained with DAPI (1 µg/ml;
Sigma-Aldrich) before embedding the slides in the mounting
medium (ibidi). The images were captured using either a Zeiss
microscope with AxioVision Rel. 4.7 (Carl Zeiss Microscopy
GmbH, Jena, Germany) or an inverse Leica SP5 Mid-multi-
photon system (Leica, Wetzlar, Germany) using a × 25 (0.95
NA) water immersion objective or × 40/1.3 NA oil objective
(Leica). The negative controls without first antibody showed
no staining. RGS5 staining gave negative results and, because
antibodies could not be validated using a positive control, the
results are not shown.
Microarray and PCR Array Validation
RNA Isolation
The ASC and HRMVPC (three biological replicates each)
were cultured for 7 days. Then, the cells were trypsinized,
washed, and RNA-isolated using Qiagen RNeasy mini Kit
(Qiagen, Hilden, Germany). RNA quality was tested by capillary
electrophoresis on an Agilent 2100 bioanalyzer (Agilent, Santa
Clara, CA, United States) and high quality (RNA integrity values
≥9) was confirmed.
Microarray
Gene expression profiling was performed using human HTA-
2_0-st-type arrays (Affymetrix, Thermo Fisher Scientific). The
biotinylated antisense cRNA was prepared, according to the
standard labeling protocol, with the GeneChip R© WT Plus
Reagent Kit and the GeneChip R© Hybridization, Wash, and
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Stain Kit. The hybridization on the chip was performed
on a GeneChip Hybridization oven 640, then dyed in the
GeneChip Fluidics Station 450, and thereafter scanned with a
GeneChip Scanner 3000.
Bioinformatics
A custom CDF version 22 with ENTREZ-based gene definitions
was used to annotate the arrays (Dai et al., 2005). The
raw fluorescence intensity values were normalized by applying
quantile normalization and RMA background correction. An
ANOVA was performed to identify differentially expressed
genes using a commercial software package (SAS JMP11
Genomics, version 7; SAS Institute, Cary, NC, United States).
A false positive rate of a = 0.05 with FDR correction
was taken as the level of significance. Gene Set Enrichment
Analysis (GSEA) was used to determine whether the defined
sets of genes exhibit a statistically significant bias in their
distribution within a ranked gene list using the R software
packages EnrichmentBrowser (Geistlinger et al., 2016). KEGG
pathway analysis was performed, focusing on apparently relevant
pathways1.
The raw and normalized data are deposited in the Gene
Expression Omnibus database (accession no. GSE144605)2.
PCR Array
The selected genes were validated using RT2 Custom Profiler
PCR Arrays (Supplementary Table S2; Qiagen, Hilden,
Germany), according to the manufacturer’s instructions, using
a LightCycler R© 480 (Roche Life Science, Mannheim, Germany).
These PCR arrays were also performed on RNA samples from
HUVEC and HRMVEC cultured for 5 days in 1/4 ECGM-2
NG/HG (three and one biological replicate, respectively).
Multiplex Cytokine Analysis of
Conditioned Media
The angiogenic growth factors in CM derived from either
CC angiogenesis assays or monocultures were analyzed
with a bead-based immunoassay (LEGENDplexTM Human
Angiogenesis Panel 1; BioLegend, San Diego, CA, United States)
by following the manufacturer’s instructions. Briefly, the
samples and the standards were loaded in a 96-well V-bottom
plate, followed by incubation with premixed capture beads for
2 h at room temperature (RT) on a plate shaker. After two
washing steps with wash buffer, the detection antibodies were
added for 1 h at RT to form capture bead/analyte/detection
antibody sandwiches. LEGENDplexTM Streptavidin-PE was
then added directly after incubation for 30 min at RT.
After a final washing step, the samples were transferred
to fluorescence-activated cell sorting tubes and analyzed
using BD FACS Canto II (Becton Dickinson). The data





All results are expressed as mean ± standard deviation; n
represents the number of biological replicates or, if not possible to
test the different donors, the technical replicates in independent
experiments. Statistical analyses were performed using GraphPad
Prism 7 (GraphPad Software, San Diego, CA, United States).
Differences between experimental groups were analyzed after
normality testing by one- or two-way ANOVA (repeated-
measures, RM, if applicable) with post hoc tests as indicated.
P ≤ 0.05 was considered as statistically significant (∗p ≤ 0.05,
∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, and ∗∗∗∗p ≤ 0.0001). For comparison
and correlation analysis of the microarray, PCR array, and flow
cytometry data, the programming language R was used. Volcano
plots were generated using the R package ggplot2.
RESULTS
ASC and Retinal Pericyte Morphology
and Growth Curves Differ, but the MSC
Marker Expression Is Similar
To compare the basic characteristics of ASC and HRMVPC,
cell morphology, growth curves, and expression of typical MSC
markers were assessed. Both cell types had a typical fibroblastoid
morphology, but both immortalized Bmi-HRMVPC, used first
for comparison, and HRMVPC, used later to account for
potential donor differences, appeared more elongated and slender
with an apparently higher light diffraction at the cell borders
(Figure 1A). Both HRMVPC detached within seconds after
adding trypsin, in contrast to ASC that needed approximately
5 min to detach. This suggests that different proteins are
involved in cell adhesion, substantiated by the recommended
coating for primary HRMVPC. The cell sizes were comparable
after trypsinization and ranged between 19 and 21 µm. Both
HRMVPC required high seeding densities (split of maximum
1:5), whereas ASC could be seeded at low densities (200
cells/cm2) to obtain optimal cell proliferation. This also suggests
different needs for cell–cell contacts for proliferation. Using live
cell imaging, a direct comparison of the growth curves was
performed by seeding cells at 2,500 cells/cm2 and assessing
the increase of confluence (Supplementary Figure S1). For the
first 24 h, the confluence increased indistinguishably, indicating
similar kinetics for cell adhesion and spreading (Figure 1B).
Thereafter, HRMVPC proliferation was very slow in contrast
to ASC, which showed a sigmoid curve at reaching 100%
confluence after 96 h.
The ASC are characterized by the expression/non-expression
of certain surface markers (Dominici et al., 2006; Bourin et al.,
2013). Flow cytometry analyses showed that marker expression
was largely identical for ASC and HRMVPC (Figure 1C). The
heterogeneity in endoglin (CD105) expression—two isolates with
only 50% of the cells being positive—was surprising for ASC since
in previous studies all ASC uniformly expressed CD105 (Kern
et al., 2006). The HRMVPC were more heterogeneous than ASC
for Thy-1 (CD90, mean 90.7 ± 7.3%, p ≤ 0.01), CD45 (mean
5.6 ± 3.9%, non-significant), vascular cell adhesion molecule-1
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FIGURE 1 | Morphology of adipose-derived stromal cells (ASC) and human retinal microvascular pericytes (HRMVPC) and the growth curves differ, whereas the
mesenchymal stromal cells (MSC) marker expression is indistinguishable. (A) Representative images of ASC, Bmi-HRMVPC and HRMVPC. (B) Growth curves of
ASC (three different donors), HRMVPC (one donor), and Bmi-HRMVPC cell line determined by kinetic live imaging (****p ≤ 0.0001, two-way ANOVA with Sidak’s
post hoc test). (C) Surface expression of MSC positive and negative markers for ASC (n = 7 different donors), HRMVPC (HRMVPC and Bmi-HRMVPC groups, n = 6,
biological and technical replicates from three different donors), and endothelial cells (EC; n = 3, human umbilical vein endothelial cell and human retinal microvascular
endothelial cell groups) (*p ≤ 0.05 and **p ≤ 0.01, two-way ANOVA with Tukey’s post hoc test; significant differences to EC not depicted).
(VCAM-1, CD106, mean: 9.7 ± 10.7%, p ≤ 0.05), and HLA-DR
(mean 10.3 ± 14.3%, p ≤ 0.05). The EC displayed a significantly
differing phenotype as expected (p value not shown).
HRMVPC Show Impaired Interaction
With HG-Conditioned EC ECM
Compared to ASC
Beltramo et al. (2009) have shown that HG-conditioned
EC ECM reduces the adhesion and increases the apoptosis
of pericytes, mimicking the pericyte dropout found in DR.
Hypothesizing that ASC can resist these changes, adhere, and
proliferate, we compared the interaction of ASC and HRMVPC
with NG- and HG-conditioned EC ECM. First, we tested
HUVEC and then—to better mimic the microvasculature of the
retina—HRMVEC. Furthermore, we assessed first immortalized
Bmi-HRMVPC and later confirmed these data with primary
HRMVPC from different donors. Using live cell imaging, we
monitored the kinetics of ASC and HRMVPC interaction with
HG-conditioned EC ECM by measuring the percent of cell
confluence (Supplementary Figure S2). The increase of ASC
confluence was higher on EC ECM compared to culture plastic
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(Figure 2A). The HUVEC ECM, conditioned with NG, HG, or
mannitol, did not significantly affect the ASC confluence. HG
conditioning rather increased ASC confluence on HUVEC ECM,
although non-significant (Figures 2C,D). Interestingly, the ASC-
improved interaction was not observed when using HRMVEC-
derived ECM, reflecting the microvasculature of the retina
(Figure 2E). As expected, the interaction between HRMVPC
and HG-conditioned EC ECM was reduced (Figures 2B–
D), however, only significant when assessing HRMVEC ECM
(p ≤ 0.05, Figure 2E). Nevertheless, compared to ASC, the
primary HRMVPC showed reduced confluence levels, which
were significant for the first 14 h when assessing the confluence
on HUVEC ECM (p ≤ 0.05, Figure 2D) but not when assessing
the confluence on HRMVEC ECM (Figure 2E).
The differing starting points of the kinetic analysis and
the fact that the curves did not separate further over time
suggested an early effect of the HG-conditioned ECM, most
probably on cell adhesion. Unfortunately, up to now, we were
not able to provide conclusive evidence for this. Measuring the
cell spreading and counting the adherent cells 10 and 20 min
after cell seeding indicated slight but non-significant differences
between ASC and HRMVPC, but none when comparing NG-
and HG-conditioned EC ECM. The adhesion kinetics, addressing
focal adhesion dynamics as previously shown (Dreher et al.,
2013), were also inconclusive. We also found no quantifiable
measures of HG-induced ECM modifications: staining with
an advanced glycation end product-specific antibody (kindly
provided by Thomas Fleming, Heidelberg) was only detected
in positive controls after methylglyoxal treatment. Quantifying
sulfated glycosaminoglycans of NG- and HG-conditioned EC
ECM revealed no differences either. Furthermore, no significant
changes were found in gene expression upon comparing
HRMVEC (not shown as only cells from one donor were tested)
and HUVEC cultured for 5 days in NG and HG conditions
(Supplementary Figure S4C).
Human ASC Are Pro-angiogenic
Whereas HRMVPC Do Not Support
Angiogenic Network Formation
A key function of pericytes is to control endothelial cell
angiogenesis or quiescence (Teichert et al., 2017). To compare
how ASC and HRMVPC regulate angiogenesis, we established
two kinetic angiogenesis assays in vitro—one focusing on cell–
cell interactions (direct CC angiogenesis assay) and a second
one addressing paracrine factors (BM angiogenesis assay).
Both assays evaluate the endothelial cell network formation
by live cell imaging (Supplementary Figure S3A). The ASC
donor-dependently supported endothelial network formation
by increasing the network branch points (Figure 3A) and
the network length (Supplementary Figure S3B). This effect
was transient, lasting for approximately 48 h, but could be
maintained for 3 weeks upon regular medium exchange. In
general, the levels of tube formation were stronger in HUVEC
compared to HRMVEC (Fiori et al., 2020). In contrast to
ASC, HRMVPC did not support network formation, neither of
HRMVEC nor of HUVEC (Figure 3A). To determine whether
this is related to cell–cell or paracrine factor, we compared the
CM of ASC and HRMVPC (prepared from CC angiogenesis
assays) to VEGF165 addition in the BM angiogenesis assay.
CM ASC significantly induced network formation similar to
VEGF165, whereas CM HRMVPC had no effect (p ≤ 0.05,
Figure 3B). This indicates that ASC secrete angiogenic factors.
Speculating that HRMVPC produce anti-angiogenic/angiostatic
factors, we added CM from ASC or HRMVPC cocultures to
CC angiogenesis assays, respectively. Indeed CM HRMVPC
abolished the supportive function of ASC (p≤ 0.05 to p≤ 0.0001,
Figure 3C). CM ASC was not capable of converting HRMVPC to
support angiogenesis (non-significant, Figure 3D). Interestingly,
the ASC from one donor that did not support vascular network
formation in the control setting—the same donor as depicted
in Figure 3A – supported tube formation once CM ASC was
added. The ASC, which aligned to and wrapped around the
endothelial tube-like structures, showed a strong expression of
α-SMA, indicating a pericyte-like differentiation (Figure 3E).
These data clearly suggest that ASC exert a pro-angiogenic
activity by providing a matrix and by secreting angiogenic factors,
whereas HRMVPC do not support and—by secreting anti-
angiogenic factors—actively inhibit endothelial tube formation.
Gene and Protein Expression Profiling
Our data suggested that the pro-angiogenic activity discriminates
ASC from HRMVPC. To gain further insight into the
potential contributing mechanisms, we performed whole-
genome microarrays and validated data using PCR arrays, flow
cytometry, and immunofluorescence analyses. The microarray
gene expression profiling resulted in 2,533 genes more highly
expressed in ASC and 2,873 higher in HRMVPC (Figure 4A).
The KEGG pathway analysis revealed that, in ASC, the
more highly expressed genes grouped to genetic information
processing, whereas in HRMVPC, the more highly expressed
genes grouped to environmental information processing. The
selected candidate genes were validated using a PCR array
(Figure 4B). There was a strong correlation between the
microarray and the PCR array data (Spearman R = 0.95,
p< 2.2e-16).
In order to understand the different adhesion of ASC and
HRMVPC to the HG-conditioned EC ECM, we first zoomed into
cell adhesion-related genes (based on a NCBI gene query with
“cell adhesion AND ‘Homo sapiens’ [porgn:__txid9606]”) and
found 434 differentially expressed genes. The integrin subunits
alpha 1, 2, 4, and 6 (ITGA 1, 2, 4, and 6) appeared to be the
most upregulated genes in HRMVPC, whereas ASC expressed
integrin subunits alpha 5 and beta 3 (ITGA5 and ITGAB3) to a
higher level (Supplementary Figures S4A,B). Accordingly, we
assessed the surface expression of integrins by flow cytometry.
However, only integrin alpha-6 (CD49f) was heterogeneously
expressed, higher in HRMVPC (69–95%) than in ASC (13–56%)
(p ≤ 0.0001, Figure 4C).
With respect to genes related to ECM, laminin subunit a3
(LAMA3), collagen type VIII alpha 1 chain (COL8A1), and
collagen type XI alpha 1 chain (COL11A1) were more highly
expressed in HRMVPC, whereas ASC showed a high expression
of laminin subunit alpha 1 (LAMA1), tenascin C (TNC),
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FIGURE 2 | Human retinal microvascular pericytes (HRMVPC) show impaired interaction with high glucose (HG)-conditioned endothelial cells (EC) extracellular matrix
(ECM) compared to adipose-derived stromal cells (ASC). The EC, either human umbilical vein endothelial cells (HUVEC) or human retinal microvascular endothelial
cells (HRMVEC), were grown until confluence in normal glucose (NG), HG, or mannitol-supplemented medium. Then, the EC ECM was prepared as described in
section “Materials and Methods”. ASC or HRMVPC were seeded on top, and the increase in confluence was monitored using live cell imaging over 48 h.
(A) Confluence of ASC seeded on HUVEC ECM conditioned by NG, HG, or mannitol (n = 4 biological replicates; non-significant, two-way RM-ANOVA with Dunnett’s
post hoc test). (B) Confluence of HRMVPC seeded on HG-conditioned HRMVEC ECM compared to NG-conditioned ECM (n = 5 independent experiments with
HRMVPC from one donor; non-significant, two-way RM-ANOVA with Sidak’s post hoc test). (C) To account for differences in proliferative capacity, confluence data
were normalized against the NG-conditioned HUVEC ECM (line at value 1). ASC vs. Bmi-HRMVPC (n = 3 independent experiments with ASC from different donors;
non-significant, two-way RM-ANOVA with Sidak’s post hoc test). (D) ASC vs. HRMVPC interaction with NG and HG-conditioned HUVEC ECM (n = 5 independent
experiments with ASC from different donors; *p ≤ 0.05 for ASC vs. HRMVPC for the first 14 h, two-way RM-ANOVA with Sidak’s post hoc test). (E) ASC vs.
HRMPVC interaction with NG and HG-conditioned HRMVEC ECM (n = 3 independent experiments with ASC from different donors; *p ≤ 0.05 for HRMVPC
interaction with NG and HG-conditioned HRMVEC ECM for all time points, two-way RM-ANOVA with Sidak’s post hoc test).
and collagen type VI alpha 1 and 2 (COL6A1 and COL6A2)
(Supplementary Figures S4A’,B’). The HRMVPC expressed
matrix metalloproteinase-1 (MMP1) and metalloproteinase
inhibitor 3 (TIMP3), which are involved in EC tubular
morphogenesis, at significantly higher levels than ASC did.
Finally, we studied the expression of common pericyte
markers. Some of the HRMVPC-specific genes appeared with
high standardized value scores, indicating relative strength
with functional association, within the gene set “pericytes” of
the database Harmonizome (Rouillard et al., 2016), such as
VEGF receptor 1 (FLT1), endothelin (EDN1), RGS5, MMP1,
angiopoietin-1 (ANGPT1, Ang-1), and fibulin-1 (FBLN-1).
None of the ASC-specific genes scored here (Figure 4A).
Comparing gene expression with protein expression data
(flow cytometric MFI values) gave low correlation values
(Spearman correlation R = 0.4, p = 0.2) in line with previous
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FIGURE 3 | Pro-angiogenic activity discriminates human adipose-derived stromal cells (ASC) and retinal pericytes. (A) Vascular network formation in CC
angiogenesis assay using network branch point metrics (1/mm2) of ASC/human retinal microvascular endothelial cells (HRMVEC), human retinal microvascular
pericytes (HRMVPC)/HRMVEC, and HRMVPC/human umbilical vein endothelial cells (HUVEC) monitored using live imaging (four different ASC donors, two and three
independent experiments with HRMVPC/HRMVEC and HRMVPC/HUVEC, respectively). Medium change is indicated by the box. ASC/HUVEC cocultures are not
shown. (B) Vascular network formation in a BM angiogenesis assay (n = 11 paired experiments with ASC from 11 different donors and HRMVPC from three different
donors in independent experiments; *p ≤ 0.05, one-way ANOVA with Tukey’s post hoc test). (C,D) Vascular network formation in CC angiogenesis assay, adding 1/4
ECGM-2 as control or CC angiogenesis assay-derived CM ASC or CM HRMVPC to ASC/HRMVEC (C) or HRMVPC/HRMVEC (D) cocultures (n = 3, with three
different ASC donors, independent experiments for two HRMVPC donors; *p ≤ 0.05 to ****p ≤ 0.0001, two-way RM-ANOVA with Tukey’s post hoc test).
(E) Representative images showing the expression of α-smooth muscle actin (α-SMA) in ASC/EC cocultures (dTomato EC, red; α-SMA green; DAPI, blue nuclear
counter stain and merge). Scale bar, 50 µm.
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FIGURE 4 | Differential marker expression of adipose-derived stromal cells (ASC) and human retinal microvascular pericytes (HRMVPC) assessed by microarray,
PCR array, flow cytometry, and immunofluorescence. (A) Volcano plot visualizing the microarray data showing the magnitude of change (log2-fold change, x-axis) vs.
statistical significance [-log10(p-value), y-axis] of gene expression of ASC vs. HRMVPC (each n = 3 biological replicates). Most differentially expressed genes and
putative pericyte markers are labeled. (B) Validation of microarray results using PCR array. The correlation is high (Spearman correlation R = 0.95, p < 2.2e-16). Most
differentially expressed genes and putative pericyte markers are labeled. (C) Marker expression in ASC, HRMVPC, and EC measured by flow cytometry. Percent
positivity calculated against the unstained control [n = 7 different ASC donors, n = 6 HRMVPC with three donors in independent experiments, n = 3 human umbilical
vein endothelial cells and human retinal microvascular endothelial cells (HRMVEC); ***p ≤ 0.001 and ****p ≤ 0.0001, two-way ANOVA with Tukey’s post hoc test,
p-values for EC not shown]. Correlation to microarray and PCR array is poor (Spearman correlation R = 0.4, p = 0.2) using mean fluorescence intensity values.
(D) Representative pictures of marker expression (green) in ASC, HRMVPC, and the respective cocultures measured by two-photon microscopy. dTomato HRMVEC
are shown in red. Scale bar, 100 µm.
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reports (Vogel and Marcotte, 2012). The alanyl aminopeptidase
(ANPEP/CD13) mRNA levels, for instance, appeared to be
increased in HRMVPC, whereas the flow cytometry data showed
no significant differences in protein expression. In general,
flow cytometry revealed a considerable heterogeneity in both
ASC and HRMVPC cultures. The percentage of melanoma
cell adhesion molecule (CD146)-positive cells was larger within
HRMVPC than in ASC (46 ± 28% vs. 21 ± 15%, p ≤ 0.001,
Figure 4C), whereas endosialin (CD248) was expressed by a
larger fraction of ASC (70 ± 17% vs. 44 ± 13%, p ≤ 0.001,
Figure 4C). PDGFR-β (CD140b), generally considered to be
a pericyte marker, was expressed by 98 ± 1% of ASC,
whereas in HRMVPC cultures the values varied (71 ± 24%,
p ≤ 0.001, Figure 4C). PDGFR-β expression was weak in
both ASC and HRMVEC after immunofluorescence staining
and independent of angiogenic EC coculture (Figure 4D). In
addition, the common pericyte marker NG-2 was assessed
(Bergers and Song, 2005) to validate the array data in which
NG-2 did not appear as a differentially expressed gene. NG-
2 was positive with immunofluorescence, more in HRMVPC
than in ASC, independent of EC coculture (Figure 4D), but
not detectable by flow cytometry [not detectable by extra- or
intracellular staining, most probably related to trypsinization
(Schmitt et al., 2018)]. As shown before, those ASC wrapping
around the tubular structures in the CC angiogenesis assay
were strongly positive for α-SMA (Figure 4D). In line
with the lack of angiogenenic tube formation, this did not
occur in HRMVPC/HRMVEC CC angiogenesis cultures. In
monocultures, α-SMA expression was weak and restricted to a
fraction of ASC and also of HRMVPC. The gene expression data
clearly demonstrated RGS5 as a differentially expressed pericyte
marker (Figure 4A). However, we were not able to assess RGS5
protein expression by flow cytometry or immunofluorescence
since negative results were obtained even in the expected
positive controls.
Overall these data demonstrate marked differences in gene
expression profiles and document a considerable degree of
heterogeneity in ASC and HRMVPC cultures, with an overlap of
the expressed markers.
Conditioned Medium Composition
Differs Significantly Between ASC and
HRMVPC
To explain the different effects of CM ASC and HRMVPC
within the angiogenesis assays, we further addressed the
differential gene expression of secreted angiogenic and anti-
angiogenic/angiostatic factors. Zooming into angiogenesis-
related genes (based on a NCBI gene query with “angiogenesis
AND ‘Homo sapiens’ [porgn:__txid9606]”), we found 450
differentially expressed genes within the microarray data sets.
ANGPT1, EDN1, ephrin-B2 (EFNB2), Bcl-2-like 1 (BCL2L1),
and transforming growth factor-beta 2 (TGFB2) stood out in
HRMVPC, whereas interleukin 6 (IL-6) and VEGF-A were
most upregulated in ASC (Supplementary Figures S4A”,B”).
TGFB1 and TGFB3 were also higher in ASC, but at the
significant limit.
To validate these results, we quantified the angiogenesis-
related growth factors in the CM of ASC and HRMVPC
mono- and CC angiogenesis cocultures. We observed some
donor-dependent variability, but a paired analysis revealed
significant changes that support the gene expression data. In
fact, ASC showed a significantly higher production of VEGF
in monocultures, which decreased in cocultures, indicating its
use (p ≤ 0.0001, Figure 5A). The values exceeded those in
HRMVPC cultures (p ≤ 0.05). The Ang-1 levels, in contrast,
were highest in HRMVPC cocultures, which were 2.8-fold higher
than in the ASC cocultures (p ≤ 0.05, Figure 5B). The Ang-2
levels increased in both ASC and HRMVPC cocultures compared
to those in the monocultures (3.8- and 6.3-fold, respectively,
non-significant, Figure 5C). Placental growth factor (PlGF), low
in all other conditions, was significantly higher in the ASC
cocultures (p ≤ 0.001, Figure 5D). The levels of epidermal
growth factor (EGF) were high in HRMVEC monocultures
but low in all other conditions (non-significant, Figure 5E).
The PECAM-1 levels were highest in HRMVEC monocultures,
significantly reduced in cocultures, and very low in ASC and
HRMVPC monocultures (p ≤ 0.01, Figure 5F). The IL-6 levels
were significantly increased in ASC cocultures compared to
their respective monocultures (p ≤ 0.05, Figure 5G). IL-8 and
fibroblast growth factor-beta (FGFb) remained unaffected by the
culture condition (Figures 5H,I). Importantly, only EGF and
FGFb were detectable in 1/4 ECGM-2 tested as control. These
data suggest that VEGF and PlGF are potential candidates for the
observed ASC pro-angiogenic potential, and Ang-1 is a candidate
for the HRMVPC anti-angiogenic/angiostatic effects.
VEGFR-2 Inhibition Efficiently Abolishes
ASC Angiogenic Supportive Capacities
Especially the high levels of VEGF in ASC/HRMVEC cocultures
and Ang-1 in HRMVPC cocultures are in line with their known
pro- and anti-angiogenic effects and prompted us to investigate
these in more detail. As observed previously (Figure 3B),
VEGF165 had similar effects as CM ASC in promoting tube
formation (Figures 6A,C). Using suramin as an inhibitor
of angiogenesis, the BM matrix dissolved and EC grew to
monolayers without forming tube-like structures (not shown).
Similar observations were made previously (Prigozhina et al.,
2013). Therefore, instead of using suramin, we added the
selective VEGFR-2 inhibitor ZM 3238811, which abolished the
supportive effect of VEGF165 in the ASC coculture angiogenesis
assay (p ≤ 0.05, Figure 6A). ZM 3238811 likewise significantly
abolished the supportive effect of CM ASC (p ≤ 0.05,
Figures 6B,C). As expected, HRMVPC showed no effect on EC
tube formation and thus were rather unaffected by the VEGFR-2
inhibitor. Interestingly, in the CC angiogenesis assays on ASC,
the inhibitor reduced the network formation affected by CM
HRMVPC even further. The inhibitory effect of CM HRMVPC
again appeared to be only transient because the branch point
values started to increase slightly after 48 h in the ASC cocultures
(Figure 6B). We verified that the inhibitor did not compromise
EC viability. These data suggest that VEGF/VEGFR-2 signaling is
required for the pro-angiogenic function of ASC.
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FIGURE 5 | Conditioned medium composition differs significantly between adipose-derived stromal cells (ASC) and human retinal microvascular pericytes
(HRMVPC). Angiogenic growth factor levels (A–I) of conditioned cell culture supernatants (CM) of mono- or cocultures measured by flow cytometry-based plex
assay (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001, one-way ANOVA with Tukey’s post hoc test) (ASC from six different donors, HRMVPC from two
different donors in independent experiments, 1/4 ECGM-2 n = 2 independent experiments).
We considered Ang-1 as an anti-angiogenic effector in CM
HRMVPC. However, both Ang-1 and Ang-2—used as control—
slightly increased tube formation in the control medium
(non-significant, Figure 6D). Ang-1 failed to reduce the pro-
angiogenic function of CM ASC. In only one culture (1),
Ang-1 inhibited the pro-angiogenic effect of CM ASC. Other
CM ASC showed an even increased angiogenic effect upon
adding Ang-1. A similar trend was also found in HRMVPC,
where Ang-1 led to a small increase in branching tubular
networks. These data suggest that HRMVPC use other/further
anti-angiogenic/angiostatic factors than just Ang-1.
DISCUSSION
Diabetic retinopathy is a frequent diabetes-associated
complication. Endothelial dysfunction ensues due to pericyte
loss. ASC have been suggested as protective and regenerative
cellular therapy and functional replacement of pericytes. Indeed
the use of ASC in several different animal models of DR brought
positive results, preventing retinal degeneration and vessel
dysfunction. However, the exact mode of action of MSC in
the retinal microenvironment is still unclear. The pericyte-like
function and the pro-angiogenic potential are the most likely
candidates. To support evidence for this, we compared the
pro-angiogenic and the pericyte-like features of ASC and
HRMVPC. Our results showed that ASC and HRMVPC: (1)
differ in morphology, growth potential, and gene and protein
expression (Figures 1, 4), (2) show marked heterogeneity
with significantly different percentages of marker-positive cells
(Figure 4), (3) exhibit different interaction with HG-conditioned
EC ECM, mimicking the DR microenvironment (Figure 2), and
(4) can be clearly discriminated by their angiogenic activity,
which involves VEGF, but probably not Ang-1 (Figures 3–6).
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FIGURE 6 | VEGFR-2 inhibition efficiently abolishes adipose-derived stromal cells (ASC) angiogenic supportive capacities, whereas Ang-1 and Ang-2 addition do not
alter effects. (A) Vascular network formation in CC angiogenesis assay. VEGF and the VEGF inhibitor ZM 3238811 were added to ASC-human retinal microvascular
endothelial cell (HRMVEC) or human retinal microvascular pericyte (HRMVPC)/HRMVEC cocultures (three different ASC donors and one HRMVPC donor; **p ≤ 0.01,
two-way RM-ANOVA with Tukey’s post hoc test). (B) Vascular network formation in CC angiogenesis assay. CM ASC or CM HRMVPC are added to ASC/HRMVEC
cocultures with the VEGF inhibitor ZM 323881 (three different ASC donors; *p ≤ 0.05, two-way RM-ANOVA with Tukey’s post hoc test). (C) Vascular network
formation in BM angiogenesis assay assessing CM ASC, CM HRMVPC, and VEGF165 in the absence and the presence of the VEGF inhibitor ZM 323881 (different
ASC donors indicated by different symbols; *p ≤ 0.05, two-way ANOVA with Sidak’s post hoc test). (D) Vascular network formation in BM angiogenesis assay
assessing CM ASC, CM HRMVPC, and control condition in the absence and the presence of recombinant Ang-1 or Ang-2 (different ASC donors or independent
HRMVPC experiments indicated by different symbols; non-significant, two-way ANOVA with Tukey’s post hoc test).
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These properties support the use of ASC as cell-based therapy
in DR but also raise potential concerns that call for a careful
risk-to-benefit analysis.
Distinction Between ASC and HRMVPC
Until now, there is no clear distinction possible between
MSC/ASC and pericytes. There is an intense discussion about the
in vivo identity of MSC that appear to reside in a perivascular
location similar to pericytes (Meirelles et al., 2006; Crisan
et al., 2008). Perivascular cells express both MSC markers
and pericyte markers. Functional tests led to regard MSC
as progenitors of pericytes (Crisan et al., 2008; Meirelles
et al., 2015; da Silva Meirelles et al., 2016; de Souza et al.,
2016; Guimaraes-Camboa et al., 2017; Hardy et al., 2017).
Comparing ASC and HRMVPC, we observed differences in
morphology and growth potential. In addition, we found a set
of differentially expressed genes with a good correlation between
microarray and PCR array results. The protein expression
analyses, however, resulted in a poor correlation to gene
expression, similar to previous reports (Vogel and Marcotte,
2012). Marker expression confirmed a distinct heterogeneity of
cell cultures. Many markers were shared, but CD105, CD106,
HLA-DR, CD49f, PDGFR-β, CD146, and CD248 revealed a
significant variation in the percentage of marker-positive cells,
which is in line with previous findings (Blocki et al., 2013;
Vezzani et al., 2016).
We now provide evidence that the pro-angiogenic capacity
discriminates ASC from HRMVPC. Hypothesizing that ASC
may replace pericytes and restore microvascular support in DR,
we first compared the interaction between ASC, HRMVPC,
and EC ECM by recapitulating the DR-like environment. The
significant reduced interaction of HRMVPC with HG-modified
EC ECM has been taken as one possible explanation for the
pericyte dropout seen in DR (Beltramo et al., 2009). We
observed only a slightly impaired adhesion of HRMVPC and no
signs of apoptosis. The ASC compared to HRMVPC, however,
showed a significantly improved interaction with HG-modified
EC ECM. As shown in a previous study (Fiori et al., 2020),
the growth factors in the ECGM-2 medium protected EC
from HG effects, which is why we reduced their concentration
to one quarter. However, despite lowering the concentration,
gene expression showed no significant changes between the
NG and the HG-cultured EC. Various further analyses did
not help to identify the molecular basis for HG-induced ECM
changes and the differing interaction of ASC and HRMVPC.
Only by using multiple particle tracking microrheology were
we able to observe HG-mediated changes in the elasticity of
HUVEC ECM, suggesting that the HG effect might relate to
the altered mechanical properties of the ECM (Hafner et al,
2020). Whether this is related to physical processes, like osmotic
shrinking, or chemical modifications, like glycation, remains to
be investigated.
Comparing next the angiogenic properties of ASC and
HRMVPC, we showed that the vascular network formation
assays can clearly discriminate ASC from HRMVPC. Whereas
the ASC induced tube formation, the HRMVPC lacked this
support and even actively inhibited network formation, both in
a paracrine fashion. The gene expression data supported our
observations, indicating a pro-angiogenic profile for ASC and an
anti-angiogenic one for HRMVPC.
In CC angiogenesis assays, the ASC underwent a pericyte-like
differentiation, characterized by α-SMA-positive cells aligning
to the tube-like structures, as shown previously (Merfeld-
Clauss et al., 2014). These authors identified that, besides
cell–cell contacts, ASC-derived VEGF and HGF and EC-
derived PDGF-BB were essential for vascular network formation
and linked activin-A to the localized α-SMA expression
(Merfeld-Clauss et al., 2010, 2014).
The observed lack of HRMVPC to support tube formation
is in line with the vessel-stabilizing function controlling EC
sprouting, proliferation, and patterning of remodeling vascular
networks (Orlidge and Damore, 1987; Simonavicius et al., 2012).
Supporting our findings, Bodnar et al. (2013) described that
pericytes, isolated from skeletal muscles, actively prevented
basal lamina matrix-induced vessel formation and even induced
regression of preformed vascular structures. Contrasting data,
however, describe the co-assembly of EC and pericytes in
3D collagen matrices (Stratman et al., 2009). In this serum-
free model, hematopoietic growth factors, such as stem cell
factor, IL-3, and stromal-derived factor a, were added, which
may explain the observed differences. Furthermore, Blocki
et al. (2013) reported that placental pericytes were best in
supporting and stabilizing the morphologically intact tube
structures, comparing pericytes from different tissues, MSC and
CD146(+)CD34(-) and CD146(-) BM-MSC. This may suggest
that either culture conditions or source and phenotype/marker
expressions define function. Interesting candidates for this
may be the differentially expressed markers identified in our
study. CD248/endosialin, more strongly expressed in HRMVPC
than in ASC, has been linked to pericyte-mediated vascular
patterning (Simonavicius et al., 2012). The α6β1 integrin/CD49f
appears to be required for perivascular localization and α-SMA
expression (Carrion et al., 2010, 2013). CD146 expression on
MSC seems to be essential for basal lamina matrix-induced
tube formation as only CD146(+)CD34(-) MSC stabilized
endothelial networks and improved endothelial sprout integrity
(Blocki et al., 2013).
Our data hint that soluble factors contribute to the pro-
and anti-angiogenic activities of ASC and HRMVPC. We
observed that the paracrine anti-angiogenic effect of CM
HRMVPC appeared to be transient. The performed growth
factor analysis suggested VEGF and PlGF as potential pro-
angiogenic factors, significantly enriched in CM from ASC
mono- and cocultures, and Ang-1 as potential anti-angiogenic
factor in CM from HRMVPC cocultures. Indeed the inhibition
of VEGFR-2 abolished the supportive effect of ASC and
CM ASC on tube formation, indicating that VEGF/VEGFR-
2 signaling is required. Furthermore, in the ASC/HRMVEC
coculture, VEGFR-2 inhibition added to the CM HRMVPC
effect, confirming the importance of VEGF. In line with
this, VEGFR-1 (Flt1) may be involved in mediating the CM
HRMVPC anti-angiogenic effect. Flt1, particularly its soluble
form, is known to antagonize VEGF–VEGFR2 interaction,
and by this, to modulate EC behavior (Eilken et al., 2017),
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FLT1 mRNA was significantly more highly expressed by
HRMVPC than by ASC.
However, we considered it more likely that Ang-1 is involved
because Ang-1–Tie2 signaling is known as an important regulator
of the maintenance of a quiescent EC phenotype (Teichert et al.,
2017). The significantly higher levels of Ang-1 in HRMVPC
cocultures suggested an anti-angiogenic function. However, tube
formation was not altered upon adding rhAng-1 or rhAng-2 as
control, neither in the control nor in the CM ASC setting. Given
the known high complexity and plasticity of pericyte-mediated
control of angiogenesis (Teichert et al., 2017), we decided to
focus on CM ASC.
We observed a clear ASC donor-dependent level in tube
formation, in line with our previous study. In this, we correlated
the growth factor concentrations in CM of ASC to the level
of vascular network support (Fiori et al., 2020). The levels
of all growth factors, except for Ang-1 and VEGF, correlated
positively to tube formation. Ang-1 correlated negatively and
VEGF showed no correlation, which was surprising given the
data shown herein that VEGF appears as the most relevant
factor for ASC’s pro-angiogenic activity. Unfortunately, in
this study, it was not possible to perform similar correlation
calculations and especially to analyze the one ASC donor that
repeatedly lacked pro-angiogenic activity on its own. Taking
both studies together, we propose that ASC secrete VEGF in
excess and that the concentration of FGFb, PECAM-1, PlGF,
Ang-1, and Ang-2—probably set off against each other—makes
up the level of tube formation. In line with this, Lehman
et al. (2012) defined the concentrations of 35 pg/ml VEGF,
110 pg/ml IL-8, and 2,050 pg/ml CXCL-5 to be required
for angiogenesis induction. In our setting, the levels of both
VEGF and IL-8 were higher in ASC mono- and cocultures
than these reported minimal concentrations. Although not yet
addressed, PlGF appears to be a highly interesting candidate
for further investigations. PlGF was found to be increased in
ASC derived from patients with coronary artery disease and
diabetes mellitus type 2. These, however, exerted significantly
reduced angiogenic activity due to increased anti-angiogenic
factors (Dzhoyashvili et al., 2014). These data suggest a
disturbed homeostasis of pro- and anti-angiogenic factors
in these patients.
ASC for Cell-Based Therapy of DR
The underlying question for this study was whether ASC can
functionally replace HRMVPC and restore vascular stabilization
in DR. As previously introduced, ASC treatment improved visual
function and delayed DR progression (Yang et al., 2010; Mendel
et al., 2013; Rajashekhar et al., 2014; Ezquer et al., 2016). In vitro
data from this and our previous studies support this since ASC
(1) resist HG-stress (Hajmousa et al., 2016; Fiori et al., 2020),
(2) reverse high glucose-induced reduction of angiogenesis in
HRMVEC, probably by reducing the oxidative stress levels (Fiori
et al., 2020) or the HG-induced proinflammatory activation of
EC (Hajmousa et al., 2018), (3) show improved interaction with
HG-conditioned HUVEC ECM compared to HRMVPC (shown
here), (4) have a pro-angiogenic activity which discriminates
them from HRMVPC (shown here), and finally (5) act as
functional pericyte-like cells in vivo (Hajmousa et al., 2018;
Terlizzi et al., 2018).
However, the pro-angiogenic activity of ASC may pose a
certain risk for ASC-based therapies. The angiogenic factors
are crucial for DR development and progression, with VEGF
being the most relevant. That is why ocular anti-VEGF therapy
has been introduced (Stitt et al., 2016). In 2017, three patients
have been reported to become blind after adipose “stem cell”
injection for age-related macular disease treatment (Kuriyan
et al., 2017). Ocular hypertension, hemorrhagic retinopathy,
vitreous hemorrhage, combined traction, and rhegmatogenous
retinal detachment have been reported. Furthermore, in a non-
diabetic transgenic model with damage of the neurovascular
unit in the retina, intravitreal MSC injection, in fact, worsened
the vascular damage by inducing cataract, increasing the loss of
pericytes with subsequent retinal vasoregression, and provoking
inflammatory responses (Huang et al., 2019). Furthermore, MSC-
derived extracellular vesicles have been shown to impair the
pericyte-stabilizing function by inducing pericyte detachment,
migration, and angiogenesis in vitro (Beltramo et al., 2014).
Non-clinical data, however, argue in favor of ASC safety and
efficacy, showing that MSC readily adapt to the local milieu and
orchestrate repair depending on the needs by secreting either
pro- or anti-angiogenic factors. Ezquer et al. (2016) at least
observed no signs of increased intraocular angiogenic growth
factors, rather of the anti-angiogenic factor thrombospondin
1, and no effect on the blood vessels after ASC injection.
In a model of corneal wound healing, locally administered
MSC likewise efficiently reduced the angiogenic and the
inflammatory processes (Oh et al., 2008). Most importantly,
Mendel et al. (2013) observed that the ASC therapeutic effects
were exactly the needed ones: after vessel destabilization,
ASC promoted vessel regrowth, whereas pretreatment with
ASC prevented capillary dysfunction. As our observations are
based only on in vitro experiments, we consider it imperative
to investigate the therapeutic mode of action and especially
the timing of cell application in suitable non-clinical models
in more detail to assure a safe and efficacious therapy.
It is also critical to address the question whether to use
autologous or allogeneic cells as Cronk et al. (2015) already
documented that ASC from diabetic animals have impaired
function compared to their healthy counterparts. Furthermore,
it would be interesting to understand whether the pro-
angiogenic activity is shared by the whole ASC population
or belongs to certain subpopulations as already suggested
(Blocki et al., 2013; Sherman et al., 2017; Wang et al., 2018).
Defining marker combinations that attribute to the observed
function may help to fine-tune the therapeutic activity of
ASC. The subtypes with increased angiogenic function could
be better suited for wound healing approaches, whereas the
subtypes with stabilizing features might be advantageous for
DR or tumor treatments. Our assay platform, in line with the
gene and the protein expression data sets, offers a valuable
basis for expansion.
In summary, our data support the use of ASC as candidates
for a cell-based therapy in early stages of DR, suggesting that they
can replace pericytes and even counteract vasoregression through
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the secretion of pro-angiogenic factors, mainly VEGF. However,
the ASC-mediated pro-angiogenic activity may pose a risk to
disease progression toward proliferative DR. Thus, a deeper
study of the pro-angiogenic capacity of ASC may represent the
turning point in the development of cell-based approaches in the
treatment of DR. We suggest a careful risk-to-benefit analysis,
including the characterization of the pro-angiogenic factors and
their interaction and the regulation of their secretion, together
with the definition of the optimal time point for ASC application,
to take full advantage of the ASC therapeutic features.
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FIGURE S1 | Workflow for kinetic analysis of cell proliferation using
IncuCyteZOOM. 1. Using the IncuCyteZOOM live imaging device, phase contrast
images of cells are automatically collected at defined time intervals (contrast and
brightness of micrographs adapted for better visibility). In general, 4 to 8 replicates
are run. 2. With an automated tool, a segmentation mask is assigned that closely
resembles the actual cell size, morphology and confluence state. This
mask/processing definition can be refined and optimized on different selected
micrographs. 3. Using this processing definition, the confluence analysis mask is
cross-checked on individual micrographs for each time point and of different
experiments and if required further optimized. 4. Kinetic plots of respective
analyses metrics are finally generated by the IncuCyte software and results
depicted as phase object confluence in percent for each time point. Raw data are
exported for further evaluation. Visual confirmation is possible via export of images
and movies.
FIGURE S2 | Workflow for analyzing the interaction of ASC and HRMVPC with
HG-conditioned EC ECM. 1. Using the IncuCyteZOOM, the proliferation of seeded
EC, cultured under NG or HG conditions, is followed (contrast and brightness of
micrographs increased). Upon reaching 100% confluence, the ECM is prepared
by lysing the EC. 2. Intactness of the ECM is verified by brilliant blue stain. 3. Then
ASC or HRMVPC are seeded on the ECM (contrast and brightness of micrograph
increased). 8 replicates were run.4. By using an optimized segmentation
mask/processing definition, 5. the adhesion and proliferation kinetics are analyzed
for each time point using different metrics: number of cells/image, average size of
cells and percent confluence, respectively. 6. To allow for quantitative comparison
between ASC and HRMVPC, confluence values were normalized against the
respective NG-modified EC ECM control, values set as 1.
FIGURE S3 | Kinetic analyses of angiogenesis assays. (A) 1. To detect network
formation, phase contrast and fluorescence images are automatically recorded at
defined time intervals in the IncuCyteZOOM using the tiled field of view (FOV)
imaging mode. 3 to 8 replicates were run. 2. Using the integrated Angiogenesis
Analysis Module, the fluorescence signal is used to quantify assay metrics: tube
length and branch points for each time point. 3. The angiogenesis algorithm
assigns a segmentation mask to resemble the vascular network. Exemplary
micrographs depict network formation in CC angiogenesis (3A-C) and BM
angiogenesis assay (4A, B). 5. Finally, kinetic data of angiogenesis metrics are
plotted and exported for further evaluation (5A, B). (B) Comparison of network
branch points and network length used as metrics to quantify network formation.
FIGURE S4 | Differential gene expression of ASC and HRMVPC, and HUVEC
cultured under normal or high glucose conditions. (A) Volcano plots visualizing
microarray data depicting statistical significance (-log10(p-value), y-axis) versus
magnitude of change (log2fold change, x-axis) of gene expression of ASC versus
HRMVPC zooming into categories adhesion (A), ECM (A’) and secreted factors
(A”), each n = 3 biological replicates. (B) Corresponding volcano plots of PCR
array data used for validation of microarray data, separating the same categories:
adhesion (B), ECM (B’) and secreted factors (B”), each n = 3 biological replicates.
There was an overall high correlation between microarray and PCR array data
(Spearman correlation R = 0.95, p < 2.2e−16). (C) Volcano plot of PCR array data
comparing HUVEC cultured for 5d in normal (NG) and high glucose (HG)
conditions, n = 3 biological replicates, non-significant. Volcano plots were
generated using the R package ggplot2. Similar data were obtained with
HRMVECs (not shown, as only n = 1 biological replicate was analyzed in 3
independent experiments).
TABLE S1 | Antibodies used for flow cytometry AF- Alexa Fluor, APC-
Allophycocyanin, FITC- Fluorescein isothiocyanate, PE- Phycoerythrin.
TABLE S2 | Gene list, Custom RT2 PCR Array.
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